abrdn

Funding rounds backed by abrdn.

Export CSV
Funding disclosed in full
$208M
Median round
$66M
Rounds in calculation
3
3 rounds
LatestLargest
Funding rounds with company descriptions, amounts, stages and announcement dates
CompanyRoundMarketInvestorsAnnouncedDetails
Abcuro

Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases

$66MSeries DBiotechUnited States
17 participantsabrdnBain Capital Life SciencesEurofarma VenturesForesite CapitalKaitai CapitalMass General Brigham VenturesNancy ChangNew Enterprise Associates (NEA)New Leaf Venture PartnersPontifaxRA Capital ManagementRedmile GroupRock Springs CapitalSamsara BioCapitalSanofi VenturesShang BaySoleus Capital
Epicrispr Biotechnologies

Develops programmable epigenetic medicines to treat genetic diseases like FSHD

$90MSeries CBiotechUnited States
9 participantsabrdnAngelini VenturesCormorant Asset ManagementDuquesne Family OfficeFidelity Management & Research CompanyJanus Henderson InvestorsOctagon CapitalReadout CapitalSanofi Ventures
Third Arc Bio

Develops novel multifunctional antibodies for oncology and immunology & inflammation indications

$52MSeries A+BiotechUnited States
11 participantsAbbVie VenturesabrdnAlderline GroupAndreessen Horowitz (a16z)BVF Partners LPGalapagos NVGoldman Sachs Alternatives Life SciencesHillhouse InvestmentMarshall WaceOmega FundsT. Rowe Price Associates